26.Jul.2018

Patient enrollment for a phase III study has been completed

This is a multicenter, randomized, double blind, parallel-group, placebo- and active-controlled study.
The study participants include healthy male volunteers, ages 18 to 45. The planned duration of treatment will be more than 20 weeks.

The study aim is to evaluate the efficacy and safety of a drug in patients with moderately to severely active rheumatoid.

The OCT team is responsible for site selection, monitoring, interaction with local ethical committees, project management, logistics, project plan development and clinical monitoring.